177 related articles for article (PubMed ID: 26708273)
1. FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations.
Tachi K; Shiraishi A; Bando H; Yamashita T; Tsuboi I; Kato T; Hara H; Ohneda O
Cancer Sci; 2016 Mar; 107(3):281-9. PubMed ID: 26708273
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
3. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
[TBL] [Abstract][Full Text] [Related]
4. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
[TBL] [Abstract][Full Text] [Related]
5. Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties.
Liu X; Huang J; Xie Y; Zhou Y; Wang R; Lou J
Med Sci Monit; 2019 Nov; 25():8905-8912. PubMed ID: 31760402
[TBL] [Abstract][Full Text] [Related]
6. Mammospheres of hormonal receptor positive breast cancer diverge to triple-negative phenotype.
Laranjo M; Carvalho MJ; Costa T; Alves A; Oliveira RC; Casalta-Lopes J; Cordeiro P; Botas F; Abrantes AM; Paiva A; Oliveira C; Botelho MF
Breast; 2018 Apr; 38():22-29. PubMed ID: 29182983
[TBL] [Abstract][Full Text] [Related]
7. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 represses the molecular phenotype of basal breast cancer cells.
Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
[TBL] [Abstract][Full Text] [Related]
11. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
[TBL] [Abstract][Full Text] [Related]
12. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.
Karthik GM; Ma R; Lövrot J; Kis LL; Lindh C; Blomquist L; Fredriksson I; Bergh J; Hartman J
Cancer Lett; 2015 Oct; 367(1):76-87. PubMed ID: 26208432
[TBL] [Abstract][Full Text] [Related]
15. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
[TBL] [Abstract][Full Text] [Related]
16. FoxA1 as a lineage-specific oncogene in luminal type breast cancer.
Yamaguchi N; Ito E; Azuma S; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Tatsuta K; Inoue J; Semba K; Watanabe S
Biochem Biophys Res Commun; 2008 Jan; 365(4):711-7. PubMed ID: 18039470
[TBL] [Abstract][Full Text] [Related]
17. CD44hiCD24lo mammosphere-forming cells from primary breast cancer display resistance to multiple chemotherapeutic drugs.
Ji P; Zhang Y; Wang SJ; Ge HL; Zhao GP; Xu YC; Wang Y
Oncol Rep; 2016 Jun; 35(6):3293-302. PubMed ID: 27109463
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
19. miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1.
Shen SQ; Huang LS; Xiao XL; Zhu XF; Xiong DD; Cao XM; Wei KL; Chen G; Feng ZB
Oncol Rep; 2017 Jul; 38(1):368-376. PubMed ID: 28534958
[TBL] [Abstract][Full Text] [Related]
20. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
Shi YF; Lu H; Wang HB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]